263 related articles for article (PubMed ID: 22886699)
1. Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.
Yuan B; Feng JQ; Bowman S; Liu Y; Blank RD; Lindberg I; Drezner MK
J Bone Miner Res; 2013 Jan; 28(1):56-72. PubMed ID: 22886699
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia.
Yuan B; Takaiwa M; Clemens TL; Feng JQ; Kumar R; Rowe PS; Xie Y; Drezner MK
J Clin Invest; 2008 Feb; 118(2):722-34. PubMed ID: 18172553
[TBL] [Abstract][Full Text] [Related]
4. Expression and distribution of SIBLING proteins in the predentin/dentin and mandible of hyp mice.
Zhang B; Sun Y; Chen L; Guan C; Guo L; Qin C
Oral Dis; 2010 Jul; 16(5):453-64. PubMed ID: 20233318
[TBL] [Abstract][Full Text] [Related]
5. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.
Liu S; Guo R; Simpson LG; Xiao ZS; Burnham CE; Quarles LD
J Biol Chem; 2003 Sep; 278(39):37419-26. PubMed ID: 12874285
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
7. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling.
Martin A; Liu S; David V; Li H; Karydis A; Feng JQ; Quarles LD
FASEB J; 2011 Aug; 25(8):2551-62. PubMed ID: 21507898
[TBL] [Abstract][Full Text] [Related]
8. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
9. SPR4-peptide alters bone metabolism of normal and HYP mice.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Mar; 72():23-33. PubMed ID: 25460577
[TBL] [Abstract][Full Text] [Related]
10. Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice.
Liang G; Katz LD; Insogna KL; Carpenter TO; Macica CM
Calcif Tissue Int; 2009 Sep; 85(3):235-46. PubMed ID: 19609735
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype.
Liu S; Guo R; Tu Q; Quarles LD
J Biol Chem; 2002 Feb; 277(5):3686-97. PubMed ID: 11713245
[TBL] [Abstract][Full Text] [Related]
12. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
[TBL] [Abstract][Full Text] [Related]
13. Increased Col10a1 expression is not causative for the phenotype of Phex-deficient Hyp mice.
Yorgan T; Rendenbach C; Jeschke A; Amling M; Cheah KS; Schinke T
Biochem Biophys Res Commun; 2013 Dec; 442(3-4):209-13. PubMed ID: 24269824
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype.
Erben RG; Mayer D; Weber K; Jonsson K; Jüppner H; Lanske B
J Bone Miner Res; 2005 Jul; 20(7):1149-60. PubMed ID: 15940367
[TBL] [Abstract][Full Text] [Related]
15. Dynamic modulation of prohormone convertase 2 (PC2)-mediated precursor processing by 7B2 protein: preferential effect on glucagon synthesis.
Helwig M; Lee SN; Hwang JR; Ozawa A; Medrano JF; Lindberg I
J Biol Chem; 2011 Dec; 286(49):42504-42513. PubMed ID: 22013069
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of FGFR Signaling Partially Rescues Hypophosphatemic Rickets in HMWFGF2 Tg Male Mice.
Xiao L; Du E; Homer-Bouthiette C; Hurley MM
Endocrinology; 2017 Oct; 158(10):3629-3646. PubMed ID: 28938491
[TBL] [Abstract][Full Text] [Related]
17. Complex intrinsic abnormalities in osteoblast lineage cells of X-linked hypophosphatemia: Analysis of human iPS cell models generated by CRISPR/Cas9-mediated gene ablation.
Nakanishi T; Yamazaki M; Tachikawa K; Ueta A; Kawai M; Ozono K; Michigami T
Bone; 2024 Apr; 181():117044. PubMed ID: 38331306
[TBL] [Abstract][Full Text] [Related]
18. Novel regulators of Fgf23 expression and mineralization in Hyp bone.
Liu S; Tang W; Fang J; Ren J; Li H; Xiao Z; Quarles LD
Mol Endocrinol; 2009 Sep; 23(9):1505-18. PubMed ID: 19556340
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
20. Osteocyte-specific deletion of Fgfr1 suppresses FGF23.
Xiao Z; Huang J; Cao L; Liang Y; Han X; Quarles LD
PLoS One; 2014; 9(8):e104154. PubMed ID: 25089825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
